SNV-601
Immuno-Oncology
Metabolic rescue of exhausted T-cells in the tumor microenvironment. >70% tumor eradication in primary IO-resistant models. CAR-T complete response rescue (6/7 vs 1/7). An orthogonal mechanism to every existing checkpoint inhibitor and cell therapy.
Therapeutic rationale
The immune system has the weapon. It runs out of fuel.
Checkpoint inhibitors unlock T-cell anti-tumor potential. But only ~12% of patients achieve objective responses across approved monotherapy labels (Haslam & Prasad, JAMA Network Open 2019). The remaining 88% represent the treatment-resistant majority.
The problem is metabolic. The tumor microenvironment is glucose-depleted. T-cells that depend on glucose for ATP production exhaust before they can clear the tumor. Unlocking a starving T-cell with a checkpoint inhibitor does not make it effective. It makes it active and unable to sustain that activity.
The BMI-survival paradox illuminates this: patients with BMI \u226525 consistently show 28\u201351% better survival on checkpoint inhibitors across six independent meta-analyses (>10,000 patients). The signal is not in the drug. It is in the patient's metabolic reserve. This is a systemic, metabolic variable that current IO therapies do not address.
SNV-601 addresses the metabolic bottleneck directly. By providing an alternative fuel (ketone bodies) that T-cells can oxidize but glycolysis-dependent tumor cells cannot, it creates a metabolic advantage for anti-tumor immunity.
Published evidence
From zero response to >70% eradication.
Preclinical models of primary IO resistance and clinical BMI-survival data.
Ferrere et al., JCI Insight 2021 (PMID: 33320838)
>70% tumor eradication in TC-1 primary anti-PD-1 resistant model with metabolic intervention + checkpoint blockade, versus zero response with checkpoint inhibition alone. Rechallenge resistance confirmed durable immunological memory. The metabolic intervention converted complete non-responders into durable complete responders.
Liu et al., Blood/ASH 2024
Oral BHB supplementation with CAR-T therapy produced complete responses in 6/7 DLBCL xenografts versus 1/7 with standard CAR-T alone. The metabolic intervention rescued CAR-T cell function in the metabolically hostile tumor microenvironment.
Murphy et al., 2024
23.1% cure rate in an engineered ICB-resistant prostate cancer model. Immunotherapy is considered futile in prostate cancer. Metabolic intervention produced durable cures in a setting where no approved therapy works.
Dai et al., 2021 (CT26 colon)
Ketone + anti-CTLA-4 combination: 8/11 survivors versus 5/12 with standard combination therapy. Metabolic intervention shifted the survival curve in an already partially responsive model.
Lussier et al., 2016 (PMID: 27178315)
Metabolic intervention reduced expression of immune checkpoint molecules PD-1, CTLA-4, and PD-L1 on tumor-infiltrating lymphocytes in a glioma model. Direct modulation of the checkpoint axis through metabolic state.
BMI-survival meta-analyses (6 independent studies, >10,000 patients)
Patients with BMI ≥25 show 28–51% better survival on checkpoint inhibitors across melanoma, NSCLC, RCC, urothelial, and other solid tumors. The consistency across tumor types and independent cohorts argues for a systemic metabolic mechanism, not a tumor-specific effect.
Mechanism of action
Three-node mechanism: fuel, remodel, exploit.
SNV-601 engages anti-tumor immunity through three simultaneous, complementary mechanisms.
1. Immune cell metabolic rescue
Tumor-infiltrating lymphocytes (TILs) exhaust in the glucose-deprived tumor microenvironment. Ketone bodies provide an alternative fuel source, restoring T-cell ATP production, cytokine secretion, and proliferative capacity. Published evidence: Ferrere 2021 (>70% eradication), Liu 2024 (CAR-T rescue 6/7 CR).
2. Tumor microenvironment remodeling
Metabolic intervention reduces immunosuppressive signaling within the TME. Lussier 2016 showed reduced PD-1, CTLA-4, PD-L1 expression. NLRP3 inflammasome inhibition (Youm 2015) reduces myeloid-derived suppressor cell activity. The TME shifts from immunosuppressive to immunopermissive.
3. Tumor cell metabolic vulnerability
Cancer cells dependent on glycolysis (Warburg effect) are selectively disadvantaged when the systemic metabolic environment shifts. Immune cells can oxidize ketones; glycolysis-dependent tumor cells cannot. The metabolic intervention creates a competitive advantage for anti-tumor immunity.
Target engagement
Six validated molecular targets.
Each target is independently validated in the peer-reviewed literature.
Partnership thesis
An orthogonal adjuvant for every IO franchise.
SNV-601 does not compete with checkpoint inhibitors. It rescues the patient population that checkpoint inhibitors fail. The mechanism is orthogonal: metabolic fuel for exhausted T-cells, TME remodeling, and exploitation of tumor metabolic vulnerability. This combines with, rather than replaces, existing IO therapy.
Every PD-1/PD-L1/CTLA-4 franchise facing response rate plateaus, LOE timelines, or biosimilar competition represents a partnership opportunity. A metabolic adjuvant that converts non-responders into responders extends franchise value and expands the eligible patient population.
Tier 1 indications: glioblastoma (where the blood-brain barrier limits conventional IO and the metabolic TME is uniquely hostile) and pancreatic cancer (where stromal desmoplasia creates metabolic isolation). Both represent large unmet needs where metabolic intervention has the strongest mechanistic rationale.